Introduction: Endometrial carcinoma is now considered a common female gynecologic cancer with increasing incidence, with 13–25% of patients being still liable to recurrence and metastasis, which needs further studies to detect novel targets and new therapies. The aim of the study was evaluate tissue expression of RON, ROR1 and SUSD2 in endometrial carcinoma and atypical endometrial hyperplasia using immunohistochemistry and correlate their expression with clinical, pathological and prognostic parameters of patients.

Material and methods: We included samples from 100 patients with endometrial carcinoma. Sections from paraffin blocks were stained with RON, ROR1 and SUSD2 using immunohistochemistry. Correlations between marker expression, clinicopathological features and prognostic samples were evaluated.

Results: Upregulation of RON and ROR1 and downregulation of SUSD2 expression were found in endometrial carcinoma more than atypical endometrial hyperplasia (p < 0.001). High RON and ROR1 expression levels were significantly associated with high patient age (p = 0.003), distant metastases (p = 0.009), advanced International Federation of Gynecology and Obstetrics stage (p = 0.002), poor response to therapy (p = 0.046), and lower recurrence-free survival (RFS) rate (p = 0.002), progression-free survival (PFS) rate (p = 0.008), distant metastasis-free survival (DMFS) rate (p = 0.019) and overall survival rate (p < 0.001). Low SUSD2 expression was significantly associated with older patient age (p = 0.002), large tumor size (p = 0.003), high grade (p = 0.005), presence of adnexal invasion (p = 0.023), presence of lympho-vascular invasion (p = 0.021), extent of myometrial invasion (p = 0.002), lower RFS rate (p = 0.008), lower PFS rate (p = 0.023), and lower DMFS rate (p < 0.001).

Conclusions: Upregulation of RON and ROR1 and downregulation of SUSD2 lead to promotion of endometrial cancer cell proliferation, migration, epithelial-mesenchymal transition, and invasion.

Key words: endometrial carcinoma, RON, ROR1, and SUSD2, prognosis.

Contemp Oncol (Pozn) 2022; 26 (2): 109-122 DOI: https://doi.org/10.5114/wo.2022.118245

RON, ROR1 and SUSD2 expression in tissues of endometrial carcinoma patients. Clinicopathological and prognostic implications

Abeer M. Abdelbary1, Randa Mohamed Kaf, Mohamed Elbakry Lashin2, Ahmed Z. Alattar3, Dalia Hamouda Elsayed1, Ahmed F. Amin4, Loay M. Gertallah5, Ahmed Mohamed Yehia6

1Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
2Gynecology and Obstetrics Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
3Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
4Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
5Anesthesia and Intensive care Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
6General Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Introduction

Endometrial carcinoma is now considered a common female gynecologic cancer with increasing incidence in developed countries. It usually has good prognosis but 13–25% of patients are still liable to recurrence and metastasis [1, 2], which needs further studies for detecting novel targets and new therapies.

Cancer invasion and metastasis is responsible for poor patients’ prognosis [3], and epithelial-mesenchymal transition (EMT) has vital roles in such processes [4].

Epithelial-mesenchymal transition is the biological process by which epithelial cells lose their normal criteria and acquire mesenchymal properties, thus enabling them to invade and metastasize [5], promoting cancer progression and spread [6].

The tyrosine kinase receptor which is known as receptor d’origine nantais (RON), discovered in 1993, has been found to be overexpressed in many cancers [7, 8]. RON overexpression was associated with metastasis and poor prognosis [9]. Epithelial-mesenchymal transition, which explained invasion, metastases and progression of many cancers, was found to be mediated by several mediators as RON, ROR1 and SUSD2 (sushi domain containing 2) [10–12].

RON aberrant expression induces EMT in tumor cells, thus allowing migration, invasion and metastases [10]. So, targeting RON could be a promising cancer targeted therapy.

Although the role of RON in cancer progression has been studied in many cancers, its prognostic roles in endometrial adenocarcinoma have not been sufficiently clarified.

The recently detected Wnt receptor, ROR1 which is a tyrosine kinase-like orphan receptor, plays critical roles in embryogenesis. Aberrant ROR1 expression has been found in many cancers [11, 13]. ROR1 has various oncogenic roles in cancers [14].

It plays an oncogenic role in many tumors by increasing tumor proliferation, stimulating stemness [15], and activating EMT [12].

SUSD2 was primarily detected in mouse as a tumor-reversing gene. Human SUSD2 is located on chromosome 22 and encodes an 822-mino acid type I membrane protein containing Sushi domains, which play important roles in adhesions between cells and cell-matrix adhesion [16]. Recent-
ly, dysregulated expression of SUSD2 was found in many cancers and associated with cancer progression, pointing to its oncosuppressive roles in cancers.

The aim of this study was to evaluate tissue expression of RON, ROR1 and SUSD2 in endometrial carcinoma and atypical endometrial hyperplasia using immunohistochemistry and correlate their expression with clinical, pathological and prognostic parameters of patients.

Material and methods

In the present study we included samples from 100 patients with endometrial carcinoma.

Cases were primarily collected by endometrial biopsy in the Gynecology and Obstetrics Department diagnosed in the Pathology Department. Cases underwent the operations of total abdominal hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy in the Gynecology and Obstetrics Department and General Surgery Department, Faculty of Medicine, Zagazig University Hospitals. All surgically operated samples were sent to the Pathology Department for final diagnosis, grading and staging.

Patients were sent to the Medical Oncology Department and to Clinical Oncology and Nuclear Medicine for further management and follow-up for survival and recurrence.

We included 100 tissue blocks containing samples from patients with endometrial carcinoma and adjacent tissues of atypical endometrial hyperplasia.

Exclusion criteria

Cases with insufficient material in paraffin blocks and cases diagnosed with other endometrial malignancies such as endometrial stromal sarcoma and leiomyosarcoma were excluded.

Immunohistochemistry

For immunohistochemistry sections were incubated with primary anti-RON (1 : 500; ab52927; Abcam, Cambridge, Cambridgeshire, UK), anti-ROR1 (1 : 50, #564464, BD Biosciences, USA) and anti-SUSD2 antibodies (Rabbit polyclonal, Sigma) using the Leica Bond RX system (Leica Microsystems, USA) at a dilution of 1 : 100 at 4°C overnight.

Evaluation of RON, ROR1 and SUSD2 expression in stained tissues

The stained sections were evaluated by assessment of staining intensity and staining percentage. The staining intensity was divided into 0 (no stain), 1 (weak stain), 2 (moderate stain), and 3 (strong stain).

The staining distribution percentages were 0 (no staining), 1 (1–25%), 2 (25–50%), and 3 (50–100%).

Multiplying scores of intensity and percentage yields final stain scores from 0 to 12. We considered a score of 4 as a cut point below which scores are considered low and above which scores are considered high to facilitate statistical analysis.

Statistical analysis

All statistics were performed using SPSS Statistics 22.0 for Windows (IBM Corp.). Continuous variables were expressed as the mean ±SD and median (range), and the categorical variables were expressed as a number (percentage). Percentages of categorical variables were compared using Pearson’s chi-square test or Fisher’s exact test as appropriate.

Recurrence free-survival (RFS) was calculated as the time from surgery to date of recurrence or the most recent follow-up contact that the patient was known to be recurrence free. Progression-free survival (PFS) was calculated as the time from start of treatment to the date of disease progression or the most recent follow-up contact that the patient was known to be progression free. Overall survival (OS) was calculated as the time from diagnosis to death or the most recent follow-up contact (censored). Stratification of RFS, PFS, distant metastasis-free survival (DMFS), and OS rates were estimated using a Kaplan-Meier plot, and compared using the log-rank test. All tests were two sided. A \( p \)-value < 0.05 was considered significant.

Table 1. Association between RON, ROR1 and SUSD2 expression and histopathology

| Factor          | Endometrial carcinoma (N = 100) | Atypical endometrial hyperplasia (N = 100) | \( p \)-value* |
|-----------------|---------------------------------|--------------------------------------------|---------------|
| Age             |                                 |                                            |               |
| \( \leq 55 \) years | 76 | 76 | 76 | 76 | < 0.001 |
| > 55 years      | 24 | 24 | 24 | 24 |               |
| RON             |                                 |                                            |               |
| Low             | 46 | 46 | 90 | 90 | < 0.001 |
| High            | 54 | 54 | 10 | 10 |               |
| ROR1            |                                 |                                            |               |
| Low             | 24 | 42 | 80 | 80 | 0.001 |
| High            | 58 | 58 | 20 | 20 |               |
| SUSD2           |                                 |                                            |               |
| Low             | 26 | 26 | 20 | 20 | 0.005 |
| High            | 74 | 74 | 80 | 80 |               |

* chi-square test
Results

Table 1 shows that upregulation of RON and ROR1 and down regulation of SUSD2 expression were found in endometrial carcinoma more than atypical endometrial hyperplasia ($p < 0.001$) (Fig. 1).

For RON expression in endometrial carcinoma and the association with clinicopathological parameters see Table 2 and Figure 2.

High RON expression was significantly associated with large tumor size, high grade, presence of cervical stromal invasion, presence of adnexal invasion, extent of myometrial invasion, presence of lymph node metastases, positive peritoneal cytology, advanced FIGO stage ($p < 0.001$), presence of lympho-vascular invasion ($p = 0.003$), parametrial invasion ($p = 0.004$), serosal invasion ($p = 0.004$) and presence of distant metastases ($p = 0.029$).

No significant association was found between RON expression and age of patients (Table 3).

For RON expression in endometrial carcinoma and the association with prognostic and follow-up parameters see Tables 4 and 5 and Figures 5 and 6.

High RON expression was significantly associated with poor response to therapy ($p = 0.046$), higher incidence of disease progression ($p = 0.018$) and higher incidence of tumor recurrence ($p = 0.004$).

High RON expression was significantly associated with lower RFS rate ($p = 0.002$), PFS rate ($p = 0.008$), DMFS rate ($p = 0.019$) and OS rate ($p < 0.001$).

For ROR1 expression in endometrial carcinoma and the association with clinicopathological parameters see Table 2 and Figure 3.

High ROR1 expression was significantly associated with older age of the patient ($p = 0.031$), large tumor size ($p = 0.003$), high grade ($p = 0.007$), presence of cervical stromal invasion, presence of adnexal invasion, extent of myometrial invasion, presence of lymph node metastases, positive peritoneal cytology, advanced FIGO stage ($p < 0.001$), presence of lympho-vascular invasion ($p = 0.003$), parametrial invasion ($p = 0.004$), serosal invasion ($p = 0.004$) and presence of distant metastases ($p = 0.029$).

For ROR1 expression in endometrial carcinoma and the association with prognostic and follow-up parameters see Tables 4 and 5 and Figures 5 and 6.

High ROR1 expression was significantly associated with higher incidence of disease progression ($p = 0.044$) and unfavorable survival ($p < 0.001$).

No significant association was found between ROR1 expression and poor response to therapy or tumor recurrence.

High ROR1 expression was significantly associated with lower RFS rate ($p = 0.032$), PFS rate ($p = 0.013$), DMFS rate ($p = 0.019$) and OS rate ($p < 0.001$).

For SUSD2 expression in endometrial carcinoma and the association with clinicopathological parameters see Table 2 and Figure 4.

Low SUSD2 expression was significantly associated with older patient age ($p = 0.002$), large tumor size ($p = 0.003$), high grade ($p = 0.005$), presence of adnexal invasion ($p = 0.023$), presence of lympho-vascular invasion ($p = 0.021$), extent of myometrial invasion ($p = 0.002$), serosal invasion ($p = 0.005$), presence of lymph nodes metastases ($p = 0.003$), distant metastases ($p = 0.023$), and advanced FIGO stage ($p = 0.011$).
No significant association was found between SUSD2 expression and cervical stromal invasion, positive peritoneal cytology or parametrial invasion.

For SUSD2 expression in endometrial carcinoma and association with prognostic and follow-up parameters see Tables 4 and 5 and Figures 5 and 6.

Low SUSD2 expression was significantly associated with poor response to therapy (p = 0.005), higher incidence of disease progression (p = 0.021) and higher incidence of tumor recurrence (p = 0.023).

Low SUSD2 expression was significantly associated with lower RFS rate (p = 0.008), PFS rate (p = 0.023), and DMFS rate (p < 0.001).

Discussion
In the present study we assessed levels of RON at the protein level using immunohistochemistry in endometrial...
RON, ROR1 and SUSD2 expression in tissues of endometrial carcinoma patients. Clinicopathological and prognostic implications

Carcinoma and found that RON was overexpressed in tissues and it was associated with poor clinicopathological parameters and unfavorable outcomes. These results were similar to results obtained by Qin et al. [9] and Zhuang et al. [17].

Qin et al. [9] found that high RON expression markedly increased the proliferation, migration, and invasion of malignant cells, while its knockdown had the opposite effect; additionally, targeted therapy against RON, with the RON inhibitor BMS777607, antagonizes the effects of RON overexpression.

All these results collectively showed the role of RON in increasing proliferation and progression of endometrial adenocarcinoma.

Similar roles of RON were found in different types of cancers [18, 19].

The roles of RON in cancer invasion, spread and progression are mostly due to activation of EMT, the process that was incriminated in cancer progression.

RON activation was shown to induce spindle morphology in tumor cells, thus facilitating invasion and spread [20].

Moreover, RON overexpression was found to affect many EMT biomarkers such as E-cadherin, which is a marker of intercellular adhesions in epithelial cells, and vimentin [21]. Moreover, RON expression allows endometrial carcinoma progression and promotes deep invasion into the myometrium [22].

RON also controls vimentin expression in endometrial carcinoma tissues; previous studies showed that increased vimentin expression promotes the migration and invasion of tumor cells [23].

So, RON played roles in facilitating cancer invasion and progression through induction of EMT of endometrial adenocarcinoma.

Additionally, RON could control EMT through several pathways, such as RAS-MAPK and PI-3K-Akt pathways [24], and SMAD and JAK pathways [25, 26].

Based on our results and results of previous studies, RON could regulate cell proliferation and EMT, which allow invasion and metastases in endometrial cancer (EC) cells, which promote the development of EC.

For further confirmation of the role of RON in progression of endometrial carcinoma we assessed levels of 2 other incriminated markers of EMT in endometrial carcinoma: ROR1 and SUSD2.

We found that ROR1 was overexpressed in endometrial carcinoma tissues and its expression was positively associated with progression and unfavorable patients’ outcome.
Table 3. Association between RON, ROR1 and SUSD2 expression and clinicopathological features in endometrial cancer patients (N = 100)

| Characteristics                  | All (N = 100) | RON Low (n = 46) | RON High (n = 54) | p-value | ROR1 Low (n = 42) | ROR1 High (n = 58) | p-value | SUSD2 Low (n = 26) | SUSD2 High (n = 74) | p-value |
|----------------------------------|---------------|------------------|-------------------|---------|------------------|-------------------|---------|--------------------|-------------------|---------|
|                                  | n  | %   | n  | %   | n  | %   | n  | %   | n  | %   | n  | %   | n  | %   | n  | %   | n  | %   | n  | %   |
| **Age**                          |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |
| ≤ 55 years                       | 76 | 76   | 38 | 50   | 38 | 50   | 38 | 50   | 38 | 50   | 10 | 13.2 | 66 | 86.8 | 0.002* |
| > 55 years                       | 24 | 24   | 6  | 25   | 18 | 75   | 4  | 16.7 | 20 | 83.3 | 16 | 66.7 | 8  | 33.3 | 0.003* |
| **Size**                         |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |
| < 4 cm                           | 34 | 34   | 30 | 88.2| 4  | 11.8| 30 | 88.2| 4  | 11.8| 0  | 0    | 34 | 100  | 0.003* |
| > 4 cm                           | 66 | 66   | 14 | 21.2| 52 | 78.8| 12 | 18.2| 54 | 81.8| 26 | 39.4 | 40 | 60.6 | 0.003* |
| **Grade**                        |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |
| Grade I                          | 34 | 34   | 30 | 88.2| 4  | 11.8| 30 | 88.2| 2  | 11.8| 0  | 0    | 34 | 100  | 0.005* |
| Grade II                         | 36 | 36   | 12 | 33.3| 24 | 66.7| 12 | 33.3| 12 | 66.7| 10 | 27.8 | 26 | 72.2 | 0.005** |
| Grade III                        | 30 | 30   | 2  | 6.7 | 28 | 93.3| 0  | 0   | 15 | 50   | 0  | 0    | 34 | 100  | 0.003* |
| **LVSI**                         |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |
| Absent                           | 60 | 60   | 38 | 63.3| 22 | 36.7| 38 | 63.3| 22 | 36.7| 10 | 16.7 | 50 | 83.3 | 0.021* |
| Present                          | 40 | 40   | 6  | 15   | 34 | 85   | 4  | 10   | 36 | 90   | 16 | 40   | 24 | 60   | 0.002* |
| **Extent of myometrial invasion**|    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |
| < 50%                            | 34 | 34   | 30 | 88.2| 4  | 11.8| 30 | 88.2| 2  | 11.8| 0  | 0    | 34 | 100  | 0.003* |
| > 50%                            | 66 | 66   | 14 | 21.2| 52 | 78.8| 12 | 18.2| 54 | 81.8| 26 | 39.4 | 40 | 60.6 | 0.002* |
| **Cervical stromal invasion**    |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |
| Absent                           | 44 | 44   | 34 | 77.3| 10 | 22.7| 34 | 77.3| 10 | 22.7| 8  | 18.2 | 36 | 81.8 | 0.264* |
| Present                          | 56 | 56   | 10 | 17.9| 46 | 82.1| 8  | 14.3| 48 | 85.7| 18 | 32.1 | 38 | 67.9 | 0.180* |
| **Parametrical extension**       |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |
| Absent                           | 84 | 84   | 48 | 59.4| 36 | 40.6| 48 | 59.4| 36 | 40.6| 22 | 18.8 | 62 | 81.2 | 0.180* |
| Present                          | 16 | 16   | 6  | 16.7| 10 | 83.3| 4  | 11.1| 12 | 88.9| 4  | 38.9 | 12 | 61.1 | 0.018* |
| **Serosal invasion**             |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |
| Absent                           | 64 | 64   | 38 | 59.4| 26 | 40.6| 38 | 59.4| 26 | 40.6| 12 | 18.8 | 52 | 81.2 | 0.180* |
| Present                          | 36 | 36   | 6  | 16.7| 30 | 83.3| 4  | 11.1| 32 | 88.9| 14 | 38.9 | 22 | 61.1 | 0.180* |
| **Adnexal invasion**             |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |
| Absent                           | 64 | 64   | 42 | 65.6| 22 | 34.4| 42 | 65.6| 22 | 34.4| 10 | 15.6 | 54 | 84.4 | 0.023* |
| Present                          | 36 | 36   | 2  | 5.6 | 34 | 94.4| 0  | 0   | 36 | 100 | 16 | 44.4 | 20 | 55.6 | 0.065* |
| **Peritoneal cytology**          |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |    |      |
| Negative                         | 60 | 60   | 38 | 63.3| 22 | 36.7| 38 | 63.3| 22 | 36.7| 10 | 16.7 | 50 | 83.3 | 0.021* |
| Positive                         | 40 | 40   | 6  | 15   | 34 | 85   | 4  | 10   | 36 | 90   | 16 | 40   | 24 | 60   | 0.002* |
Table 3. Cont.

| Characteristics       | All                | RON     | ROR1    | SUSD2   | p-value     | p-value     |
|-----------------------|--------------------|---------|---------|---------|-------------|-------------|
|                       | (N = 100)          | Low (n = 46) | High (n = 54) | Low (n = 42) | High (n = 58) | Low (n = 26) | High (n = 74) |
|                       | n  | %   | n  | %   | n  | %   | n  | %   | n  | %   | n  | %   | n  | %   |
| Lymph node            |                |         |         |         |     |         |     |         |     |         |     |         |     |         |
| Negative              | 60  | 60  | 38  | 63.3 | 22  | 36.7 | 38  | 63.3 | 22  | 36.7 | 10  | 16.7 | 50  | 83.3 |
| Positive              | 40  | 40  | 6   | 15   | 34  | 85   | 4   | 10   | 36  | 90   | 16  | 40   | 24  | 60   |
| Distant metastasis    |                |         |         |         |     |         |     |         |     |         |     |         |     |         |
| Negative              | 80  | 80  | 42  | 52.2 | 38  | 47.5 | 42  | 52.5 | 38  | 47.5 | 16  | 20   | 64  | 80   |
| Positive              | 20  | 20  | 2   | 10   | 18  | 90   | 0   | 0    | 20  | 100  | 10  | 50   | 10  | 50   |
| FIGO stage            |                |         |         |         |     |         |     |         |     |         |     |         |     |         |
| Stage I               | 44  | 44  | 34  | 77.3 | 10  | 22.7 | 34  | 77.3 | 10  | 22.7 | 6   | 13.6 | 38  | 86.4 |
| Stage II              | 20  | 20  | 4   | 20   | 16  | 80   | 0   | 0    | 4   | 20   | 0   | 0    | 4   | 20   |
| Stage III             | 16  | 16  | 4   | 25   | 12  | 75   | 4   | 25   | 12  | 75   | 6   | 37.5 | 10  | 62.5 |
| Stage IV              | 20  | 20  | 4   | 10   | 18  | 90   | 2   | 10   | 18  | 90   | 10  | 50   | 10  | 50   |

FIGO – International Federation of Gynecology and Obstetrics, LVSI – lymph-vascular space invasion
* chi-square test, ** chi-square test for trend

Table 4. Association between RON, ROR1 and SUSD2 expression and patients' outcome in endometrial cancer patients (N = 100)

| Outcome                  | All                | RON     | ROR1    | SUSD2   | p-value     | p-value     |
|--------------------------|--------------------|---------|---------|---------|-------------|-------------|
|                         | (N = 100)          | Low (n = 46) | High (n = 54) | Low (n = 42) | High (n = 58) | Low (n = 26) | High (n = 74) |
|                         | No.  | %   | No.  | %   | No.  | %   | n  | %   | n  | %   | n  | %   | n  | %   | n  | %   |
| Response to CRT         |                |         |         |         |     |         |     |         |     |         |     |         |     |         |     |         |     |         |
| OAR                     | 28  | 56  | 10  | 100  | 18  | 45  | 8   | 100  | 20  | 47   | 18  | 69.2 | 10  | 41.7 |
| NR                      | 22  | 44  | 0   | 0    | 22  | 55   | 0   | 0    | 22  | 52   | 8   | 30.8 | 14  | 58.3 |
| Recurrence              |                |         |         |         |     |         |     |         |     |         |     |         |     |         |     |         |     |         |
| Absent                  | 66  | 84.6 | 44  | 100  | 22  | 64.7 | 40  | 95.2 | 26  | 72.2  | 12  | 66.7 | 54  | 90   |
| Present                 | 12  | 15.4 | 0   | 0    | 12  | 35.3 | 2   | 4.8  | 10  | 27.8  | 6   | 33.3 | 6   | 10   |
| Progression             |                |         |         |         |     |         |     |         |     |         |     |         |     |         |     |         |     |         |
| Absent                  | 30  | 53.6 | 12  | 100  | 18  | 40.9 | 10  | 100  | 20  | 43.5  | 20  | 76.9 | 5   | 33.3 |
| Present                 | 26  | 46.4 | 0   | 0    | 26  | 59.1 | 0   | 0    | 26  | 56.5  | 6   | 23.1 | 10  | 66.7 |
| Metastasis              |                |         |         |         |     |         |     |         |     |         |     |         |     |         |     |         |     |         |
| Absent                  | 64  | 80   | 38  | 90.5 | 26  | 68.4 | 38  | 90.5 | 26  | 68.4  | 6   | 37.5 | 58  | 90.6 |
| Present                 | 16  | 20   | 4   | 9.5  | 12  | 31.6 | 4   | 9.5  | 12  | 31.6  | 10  | 62.5 | 6   | 9.4  |
| Mortality               |                |         |         |         |     |         |     |         |     |         |     |         |     |         |     |         |     |         |
| Alive                   | 64  | 64   | 40  | 90.9 | 24  | 42.9 | 38  | 90.5 | 26  | 44.8  | 14  | 53.8 | 50  | 67.6 |
| Died                    | 36  | 36   | 4   | 9.1  | 32  | 57.1 | 4   | 9.5  | 36  | 55.2  | 12  | 46.2 | 24  | 32.4 |

CRT – cardiac resynchronization therapy, NR – non-response, OAR – organs at risk
* chi-square test
| Outcome | All | RON | ROR1 | SUSD2 |
|---------|-----|-----|------|-------|
|         | Low | High| Low  | High  | Low  | High  | Low  | High  | Low  | High  |
|         |     |     | p-value |     |     | p-value |     |     | p-value |     |     | p-value |
|         |     |     | (N = 100) |     |     | (N = 100) |     |     | (N = 100) |     |     | (N = 100) |
| RFS     |     |     |         |     |     |         |     |     |         |     |     |         |
| Mean (months) |     |     | (95% CI) |     |     | (95% CI) |     |     | (95% CI) |     |     | (95% CI) |
| 1 year RFS (%) |     |     | 97.4 | 100 | 94.1 | 100 | 94.4 | 100 | 96.7 | 100 | 96.7 | 100 |
| 2 year RFS (%) |     |     | 89.6 | 100 | 76.5 | 100 | 77 | 63.5 | 96.7 | 100 | 96.7 |
| 3 year RFS (%) |     |     | 89.6 | 100 | 76.5 | 100 | 77 | – | 96.7 | 100 | 96.7 | 100 |
| 4 year RFS (%) |     |     | 84.9 | 100 | 65.5 | 100 | 66 | – | 91.6 | 100 | 91.6 | 100 |
| 5 year RFS (%) |     |     | 79.2 | – | – | 90 | – | 85.5 | 100 | 91.6 | 100 | 91.6 |
| PFS     |     |     |         |     |     |         |     |     |         |     |     |         |
| Mean (months) |     |     | (95% CI) |     |     | (95% CI) |     |     | (95% CI) |     |     | (95% CI) |
| 1 year PFS (%) |     |     | 64.3 | 100 | 54.5 | 100 | 56.5 | 92.3 | 40 | 92.3 | 40 |
| 2 year PFS (%) |     |     | 64.3 | 100 | 54.5 | 100 | 56.5 | 92.3 | 40 | 92.3 | 40 |
| 3 year PFS (%) |     |     | 64.3 | 100 | 21.8 | 100 | 22.6 | 55.4 | 32 | 91.6 | 32 |
| 4 year PFS (%) |     |     | 45 | – | 21.8 | – | 22.6 | – | 32 | – | 32 |
| 5 year PFS (%) |     |     | – | – | – | – | – | – | 85.5 | 100 | 91.6 | 100 |
| DMFS    |     |     |         |     |     |         |     |     |         |     |     |         |
| Mean (months) |     |     | (95% CI) |     |     | (95% CI) |     |     | (95% CI) |     |     | (95% CI) |
| 1 year DMFS (%) |     |     | 97.4 | 100 | 94.1 | 100 | 94.1 | 87.5 | 100 | 91.6 | 100 |
| 2 year DMFS (%) |     |     | 92.1 | 100 | 82.4 | 100 | 82.4 | 87.5 | 93.3 | 92.3 | 93.3 |
| 3 year DMFS (%) |     |     | 77.4 | 90.5 | 74.9 | 90.5 | 82.8 | – | 89.9 | 91.6 | 89.9 |
| 4 year DMFS (%) |     |     | 77.4 | 90.5 | 58.2 | 90.5 | 58.2 | – | 89.9 | 91.6 | 89.9 |
| 5 year DMFS (%) |     |     | 77.4 | 90.5 | – | 90.5 | – | – | 89.9 | 91.6 | 89.9 |
| OS      |     |     |         |     |     |         |     |     |         |     |     |         |
| Mean (months) |     |     | (95% CI) |     |     | (95% CI) |     |     | (95% CI) |     |     | (95% CI) |
| 1 year OS (%) |     |     | 88 | 100 | 78.6 | 100 | 79.3 | 92.3 | 86.5 | 92.3 | 86.5 |
| 2 year OS (%) |     |     | 79.3 | 100 | 61.2 | 100 | 62.8 | 92.3 | 75.5 | 92.3 | 75.5 |
| 3 year OS (%) |     |     | 66.9 | 90.5 | 44.5 | 90.5 | 45.6 | 18.5 | 72.7 | 91.6 | 72.7 |
| 4 year OS (%) |     |     | 64.4 | 90.5 | 39 | 90.5 | 39.9 | – | 72.7 | 91.6 | 72.7 |
| 5 year OS (%) |     |     | 56.8 | 90.5 | – | 90.5 | – | – | 64.1 | 91.6 | 64.1 |

DMFS – distant metastasis-free survival, OS – overall survival, PFS – progression-free survival, RFS – recurrence-free survival

* log rank test
RON, ROR1 and SUSD2 expression in tissues of endometrial carcinoma patients. Clinicopathological and prognostic implications

Similar results were reported by Liu et al. [14] and Henry et al. [27], who confirmed the role of ROR1 as a novel prognostic marker and therapeutic target in EC.

We observed that patients with high expression of ROR1 had lower OS and PFS rates in comparison with patients with low ROR1 expression levels.

We found an association between ROR1 expression and higher grade and advanced stage of endometrial carcinoma, which was similar to the results of Liu et al. [14] and those of Zhang et al. [28] in ovarian and pancreatic cancer.

ROR1 was found to play a role in cancer progression through activation of EMT through activation of Wnt signaling [29, 30], which was proved to be associated with metastasis in ovarian cancer [31].

Previous studies showed that ROR1 played an important role in the EMT process, which has a critical role in controlling cancer metastases [32, 33].

Regarding the association between ROR1 expression and survival rates, it was found that ROR1 overexpression was related to unfavorable survival rates and it could be considered a promising novel therapeutic target for recent management of EC.

The recently detected ROR1 inhibitor cirmtuzumab is a monoclonal antibody that has proven to be effective in inhibiting ROR1 signaling in ovarian cancer and chronic lymphocytic leukemia (CLL) [34, 35].

Another ROR1-targeting therapy which is called ROR1 chimeric antigen receptor T cell therapy, as described by Berger et al. [36], was tried as targeted therapy in CLL and triple negative breast carcinoma.

These new ROR1 inhibitors and targeted therapies could be beneficial to EC patients, particularly those with high expression of ROR1.

Our study confirms the prognostic role of ROR1 in endometrial carcinoma progression and points to the future benefits of ROR1-targeting therapies in EC patients.

We observed a positive association between RON and ROR1 expression in tissues of endometrial carcinoma; both biomarkers performed their work through activation of EMT and both are associated with cancer progression and unfavorable outcomes.

We assessed expression of another marker, SUSD2, which has variable prognostic roles in different cancer types.

Several studies have assessed associations between SUSD2 expression and prognosis of many cancers, e.g. breast, colon [16, 37], but its role in endometrial carcinoma has not been clarified yet.

Fig. 3. ROR1 expression in endometrial carcinoma (EC). High ROR1 expression in serous EC high grade stage III 400× (A), high ROR1 expression in endometroid EC high grade stage III 400× (B), low ROR1 expression in endometroid EC low grade stage II 400× (C), negative ROR1 expression in endometroid EC low grade stage I 400× (D).
Our study demonstrated that tissue protein expression of SUSD2 was downregulated in endometrial carcinoma tissues, its low expression was related to unfavorable prognostic and clinicopathological parameters and its expression was inversely associated with RON and ROR1 expression in tissues of endometrial carcinoma.

Similar results were obtained in hepatocellular carcinoma tissues in the study of Liu et al. [38], which showed that SUSD2 expression was reduced in malignant tissues more than adjacent non-neoplastic tissues, suggesting that SUSD2 down-regulation plays important roles in carcinogenesis and cancer progression.

A possible explanation of our results is that SUSD2 downregulation led to an increased rate of cell proliferation and reduced apoptosis; thus, SUSD2 had a tumor suppressor role and inhibited tumor growth [38].

Additionally we observed that high levels of SUSD2 markedly reduced invasiveness and migration ability of endometrial carcinoma cells, and we found that it was inversely associated with the EMT markers ROR1 and RON1.

Moreover, we found that high levels of SUSD2 expression in the tumor were associated with improved patient survival, which points to the tumor suppressor role of SUSD2. Similar results were obtained in serous ovarian carcinoma by Sheets et al. [39, 40], who reported that high SUSD2 expression could inhibit ovarian carcinoma metastasis.

Different results from ours were obtained in some studies on different cancer types. Zhang et al. [41] reported that SUSD2 expression is upregulated in EC cells, associated with unfavorable prognosis, and its downregulation improves patients’ prognosis. Additionally they concluded that SUSD2 could be considered a chemotherapeutic target in EC. Their explanation for their results was that SUSD2 participates in apoptosis and cell senescence in EC cells and thus affects invasiveness and spread.

Also the results of Xu et al. [42] showed that high expression of SUSD2 increased ovarian cancer metastasis.

Those contrasting results could be explained by differences in methods of tissue expression, subcellular localization of SUSD2 and different metastasis mechanisms [43, 44]. Also the results of Watson et al. [16] showed that high SUSD2 expression in breast cancer enhanced cancer cell invasion and metastases.

Conclusions

We conclude that upregulation of RON and ROR1 in addition to downregulation of SUSD2 might be considered
RON, ROR1 and SUSD2 expression in tissues of endometrial carcinoma patients. Clinicopathological and prognostic implications

Fig. 5. Five-year disease-free survival (DFS) rate of included patients with endometrial carcinoma (A), DFS rate in association with RON expression (B), DFS rate in association with RON and ROR1 expression (C), DFS rate in association with SUSD2 expression (D)

DFS – disease-free survival
Fig. 6. Five-year overall survival (OS) rate of included patients with endometrial carcinoma (A), OS rate in association with RON expression (B), OS rate in association with RON and ROR1 expression (C), OS rate in association with SUSD2 expression (D).

OS – overall survival
RON, ROR1, and SUSD2 expression in tissues of endometrial carcinoma patients. Clinicopathological and prognostic implications

a promoting factor for EC cells' proliferation, migration, EMT, and invasion.

**Recommendations**

We recommend performing further studies on gene expression of studied markers, aiming at their appraisal as novel therapeutic targets for treatment of endometrial adenocarcinoma.

Moreover, we recommend assessing markers' expression in different variants of endometrial carcinoma in the recent molecular classification of endometrial cancer, to detect their roles.

Pre-operative detection of glandular cells (GC) in cervical smear analysis might be a predictor for endometrial cancer local recurrence [45]. Relative telomere length (RTL) in cell-free DNA (cfDNA) for EC, and cfDNA RTL analysis might be a potential diagnostic tool for early EC detection, progression, staging, and grading.

However, further studies are needed to confirm these results focusing on high-risk patients who might benefit from this tool, as TL shortening is not specific for EC [46].

We recommend investigating correlations between studied markers' expression, pre-operative detection of GC in cervical-smear analysis and cfDNA RTL analysis for early detection of endometrial cancer recurrence.

The authors declare no conflict of interest.

**References**

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: Cancer J Clin 2013; 63: 11-30.
2. Lortet-Tieulient J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. JNCI J Natl Cancer Inst 2017; 110: 354-361.
3. Makker A, Goel MM. Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrial carcinoma: an update. Endocr Relat Cancer 2016; 23: R85-R111.
4. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275-292.
5. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014; 16: 488-494.
6. Katkoori VR, Basson MD, Bond VC, Manne U, Bumpers HL. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial-to-mesenchymal transition in colon and breast cancers. Oncotarget 2015; 6: 27763-27777.
7. Roncin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1999; 8: 1195-1202.
8. Weng TH, Yao MY, Xu XM, et al. RON and MET co-overexpression are significant pathological characteristics of poor survival and therapeutic targets of tyrosine kinase inhibitors in triple-negative breast cancer. Cancer Res Treat 2020; 52: 973-986.
9. Yu Q, Wang J, Li T, et al. RON mediates tumor-promoting effects in endometrial adenocarcinoma. Bio Med Res Int 2021; Article ID 2282916: 10.
10. Kim SA, Lee KH, Lee DH, et al. Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma. Int J Oncol 2019; 55: 513-526.
11. Chien HP, Ueng SH, Chen SC, et al. Expression of ROR1 has prognostic significance in triple negative breast cancer. Virchows Arch 2016; 468: 589-595.
12. Cui B, Zhang S, Chen L, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Can Res 2013; 73: 3649-3660.
13. Zhang S, Cui B, Lai H, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci 2014; 111: 17266-17271.
14. Liu D, Gunther K, Luis A, et al. ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target. Sci Rep 2020; 10: 13906.
15. Liu Y, Yang H, Chen T, Luo Y, Xu Z, Li Y, Yang J. Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K/AKT/mTOR signaling pathway in lung adenocarcinoma. PLoS One 2015; 10: e0127092.
16. Watson AP, Evans RL, Egland KA. Multiple functions of susho domain containing 2 (SUSD2) in breast tumorigenesis. Mol Cancer Res 2013; 11: 74-85.
17. Zhuang XP, Jin WW, Teng XD, Yuan ZZ, Lin QQ, Xu ST. c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis. Eur J Gynaecol Oncol 2015; 36: 255-259.
18. Bourn JR, Ruiz-Torres SJ, Hunt BG, Benight NM, Waltz SE. Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling. Cancer Lett 2021; 503: 75-90.
19. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 2008; 100: 1-33.
20. Ma Q, Guin S, Padhye SS, Zhou YQ, Zhang RW, Wang MH. Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein. Mol Cancer 2011; 10: 66.
21. Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci 2005; 118: 873-887.
22. Sakuragi N, Nishiya M, Ikeda K, et al. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol 1994; 53: 183-189.
23. Battaglia RA, Delic S, Herrmann H, Snider NT. Vimentin on the move: new developments in cell migration. F1000Res 2018; 7: F1000 Faculty Rev-1796.
24. Wang J, Rajput A, Kan JL, et al. Knockdown of Ron kinase inhibits its mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem 2009; 284: 10912-10922.
25. Wang MH, Zhang R, Zhou YQ, Yao HP. Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction. J Biomed Res 2013; 47: 345-354.
26. Park JS, Choi HI, Kim DH, et al. RON receptor tyrosine kinase regulates epithelial mesenchymal transition and the expression of pro-fibrotic markers via Src/Smad signaling in HK-2 and NRK49F cells. Int J Mol Sci 2019; 20: 5489.
27. Henry CE, Llamasos E, Daniels B, Coopes A, Tang K, Ford CE. ROR1 and ROR2 play distinct and opposing roles in endometrial cancer. Gynecol Oncol 2018; 148: 576-584.
28. Zhang S, Chen L, Wang-Rodriguez J, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol 2012; 181: 1903-1910.
29. Kani S, Oishi I, Yamamoto H, et al. The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase lepsion. J Biol Chem 2004; 279: 50102-50109.
30. Fukuda T, Chen L, Endo T, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci 2008; 105: 3047-3052.
31. Henry C, Hacker N, Ford C. Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis. Oncotarget 2017; 8: 112727.
32. Heerboth S, Housman G, Leary M, et al. EMT and tumor metastasis. Clin Transl Med 2015; 4: 6.
33. Tan H, He Q, Gong G, et al. miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer. Int J Oncol 2016; 48: 181-190.
34. Zhang S, Cui B, Lai H, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci 2014; 111: 17266-17271.

35. Choi MY, Widhopf GF, Ghia EM, et al. Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell 2018; 22: 951-959.e3.

36. Berger C, Sommermeyer D, Hudecek M, et al. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res 2015; 3: 206-216.

37. Pan W, Cheng Y, Zhang H, et al. CSBF/C10orf99, a novel potential cytokine, inhibits colon cancer cell growth through inducing G1 arrest. Sci Rep 2014; 4: 6812.

38. Liu X, Cai CX, Luo LM et al. Decreased expression of sushi domain containing 2 correlates to progressive features in patients with hepatocellular carcinoma. Cancer Cell Int 2016; 16: 15.

39. Sheets JN, Iwanicki M, Liu JF, et al. SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. Oncogenesis 2016; 5: e264.

40. Sheets JN, Patrick ME, Egland KA. SUSD2 expression correlates with decreased metastasis and increased survival in a high-grade serous ovarian cancer xenograft murine model. Oncotarget 2020; 11: 2290-2301.

41. Zhang S, Zeng N, Alowayed N, et al. Downregulation of endometrial mesenchymal marker SUSD2 causes cell senescence and cell death in endometrial carcinoma cells. PLoS One 2017; 12: e0183681.

42. Xu Y, Miao C, Jin C, et al. SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer. Exp Cell Res 2018; 363: 160-170.

43. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 2009; 113: 143-148.

44. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 2005; 5: 355-366.

45. Casarin J, Bogani G, Serati M, et al. Presence of glandular cells at the preoperative cervical cytology and local recurrence in endometrial cancer. Int J Gynecol Pathol 2020; 39: 522-528.

46. Benati M, Montagnana M, Danese E, et al., Aberrant telomere length in circulating cell-free DNA as possible blood biomarker with high diagnostic performance in endometrial cancer. Pathol Oncol Res 2020; 26: 2281-2289.

Address for correspondence

Randa Mohamed Kaf, MD
Pathology Department
Faculty of Medicine
Zagazig University
Zagazig, Egypt
e-mail: loayelhady@gmail.com

Submitted: 07.03.2022
Accepted: 22.05.2022